Musso Giovanni, Alberto Mella, Mariano Filippo, Cassader Maurizio, De Michieli Franco, Riva Antonella, Petrangolini Giovanna, Togni Stefano, Pinach Silvia, Gambino Roberto
MECAU Department San Luigi Gonzaga Hospital, Turin, Italy.
Department of Nephrology, Città della Salute e della Scienza Hospital, University of Turin, Turin, Italy.
Gut Microbes. 2024 Jan-Dec;16(1):2424907. doi: 10.1080/19490976.2024.2424907. Epub 2024 Dec 2.
We investigate the role of homeostatic mechanisms involved in acute, postprandial nutrient metabolism and nutrient-induced systemic inflammation in CKD presence and progression in Metabolic dysfunction-associated steatohepatitis (MASH). We assessed postprandial incretins (GLP-1 and GIP), intestinotropic hormone GLP-2, endotoxin LPS, Zonulin (a marker of intestinal permeability), hepatokines, adipokines and NF-kB activation in circulating MNCs during a meal tolerance test in 52 biopsy proven MASH patients randomized to curcumin Meriva or placebo and 26 matched controls. At baseline, MASH-CKD had a lower GLP-2 response and a 2-fold higher postprandial LPS and NF-kB activation in MNCs than MASH patients without CKD, but similar remaining postprandial or fasting parameters. Postprandial IAUC GLP-2 predicted the presence of CKD in MASH (OR = 0.43, 95%CI:0.32-0.80, = 0.008) independently of liver histology and traditional risk factors. After 72 weeks, changes in IAUC GLP-2 independently predicted the presence of CKD (OR = 0.49, 95%CI:0.21-0.73, = 0.010) and eGFR changes [β(SE) = 0.510(0.007, = 0.006] at end-of-treatment, In MASH, an impaired GLP-2 response to meals is associated with intestinal barrier dysfunction, endotoxemia and NF-kB-mediated systemic inflammation and may promote renal dysfunction and CKD. These data provide the rationale for evaluating GLP-2 analogues in MASH-related CKD.
我们研究了稳态机制在代谢功能障碍相关脂肪性肝炎(MASH)中慢性肾脏病(CKD)的存在及进展过程中,参与急性餐后营养代谢和营养诱导的全身炎症方面所起的作用。我们在一项进餐耐量试验中,对52例经活检证实为MASH的患者(随机分为姜黄素Meriva组或安慰剂组)以及26例匹配的对照者,评估了餐后肠促胰岛素(胰高血糖素样肽-1和葡萄糖依赖性促胰岛素多肽)、促肠激素胰高血糖素样肽-2、内毒素脂多糖、闭合蛋白(肠道通透性标志物)、肝源性激素、脂肪因子以及循环单核细胞中核因子-κB的激活情况。在基线时,与无CKD的MASH患者相比,MASH合并CKD患者的胰高血糖素样肽-2反应较低,餐后脂多糖水平及单核细胞中核因子-κB激活水平高2倍,但其余餐后或空腹参数相似。餐后胰高血糖素样肽-2的增量曲线下面积(IAUC)可独立于肝脏组织学和传统危险因素预测MASH中CKD的存在(比值比=0.43,95%置信区间:0.32 - 0.80,P = 0.008)。72周后,餐后胰高血糖素样肽-2的IAUC变化可独立预测治疗结束时CKD的存在(比值比=0.49,95%置信区间:0.21 - 0.73,P = 0.010)以及估算肾小球滤过率(eGFR)的变化[β(标准误)=0.510(0.007),P = 0.006]。在MASH中,对进餐的胰高血糖素样肽-2反应受损与肠道屏障功能障碍、内毒素血症及核因子-κB介导的全身炎症相关,并可能促进肾功能不全和CKD的发生。这些数据为评估胰高血糖素样肽-2类似物在MASH相关CKD中的应用提供了理论依据。